110 related articles for article (PubMed ID: 31826054)
1. Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.
Gutting T; Schulte N; Belle S; Betge J; Härtel N; Wilke J; Weers J; Ebert MP; Zhan T
J Gastrointestin Liver Dis; 2019 Dec; 28(4):503-507. PubMed ID: 31826054
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
[TBL] [Abstract][Full Text] [Related]
3. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
4. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
6. [Good remission under HER2 blockade in an advanced carcinoma of the oesophagogastric junction with only focal HER2 overexpression].
Gaiser T; Hirsch D; Hofheinz RD
Z Gastroenterol; 2017 Sep; 55(9):866-871. PubMed ID: 28787750
[TBL] [Abstract][Full Text] [Related]
7. AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).
Häussler U; Bitzer M; Bösmüller H; Clasen S; Götz M; Malek NP; Plentz RR
Z Gastroenterol; 2016 Oct; 54(10):1147-1150. PubMed ID: 27723906
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
9. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
[TBL] [Abstract][Full Text] [Related]
10. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
[TBL] [Abstract][Full Text] [Related]
12. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.
Ihnenfeld Arciénega I; Imesch P; Fink D; Dedes KJ
Target Oncol; 2015 Jun; 10(2):297-301. PubMed ID: 25511015
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
14. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
15. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE; Hozaeel W; Jäger E
Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Homann N; Pauligk C; Luley K; Werner Kraus T; Bruch HP; Atmaca A; Noack F; Altmannsberger HM; Jäger E; Al-Batran SE
Int J Cancer; 2012 Apr; 130(7):1706-13. PubMed ID: 21618509
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
Safran H; Dipetrillo T; Akerman P; Ng T; Evans D; Steinhoff M; Benton D; Purviance J; Goldstein L; Tantravahi U; Kennedy T
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):405-9. PubMed ID: 17097832
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein.
Rebischung C; Barnoud R; Stéfani L; Faucheron JL; Mousseau M
Gastric Cancer; 2005; 8(4):249-52. PubMed ID: 16328600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
